Steve Bryson, PhD,  science writer—

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Neutrophil cell subtype tied to lung function decline in stable CF

Lung function decline in adults with stable cystic fibrosis (CF) was tied to high numbers of mature low-density neutrophils, a white blood cell subtype associated with inflammatory disorders, a study suggests. While previous research showed that low-density neutrophils in CF children correlated with better lung function, the changes found…

New nanoparticles may correct genetic defects in lungs

Researchers are developing new inhalable nanoparticles designed to deliver RNA-based gene-editing therapeutics directly to the lungs, a study reports. Now shown to be effective in mice, the ultimate goal is to develop inhaled therapeutics to correct genetic defects in conditions affecting the lungs, such as cystic fibrosis (CF). “This…

Study delves into how CFTR changes its shape to be effective

Small changes in the shape of CFTR, the protein defective or absent in people with cystic fibrosis (CF), opened its gate outside the cell to allow the flow of chloride ions, a study reported. CF-causing mutations that suppress CFTR function disrupt these long-distance shape changes. By comparison, CFTR potentiator…

Environment plays big role in lung function decline in CF children

Exposure to traffic-related air pollution is an important predictor of early lung function decline in children and adolescents with cystic fibrosis (CF), a study has found. Community deprivation — reflecting poverty, housing, income, education, and health insurance coverage — was also a significant predictor of this decline in young…

CFTR Modulators Found to Improve Antibiotic Efficacy in CF: Study

CFTR modulators, approved therapies to treat cystic fibrosis (CF), showed antibacterial activity and enhanced the efficacy of some antibiotics against bacterial species commonly found in CF airways, according to a new study. “Additive effects or synergies were observed between the CFTR modulators and antibiotics against [two common] species” of…

Trikafta Found to Improve Insulin Secretion, Body Weight in CF

Treatment with Trikafta improved insulin secretion and body weight within one year in people with cystic fibrosis (CF), according to a small analysis. Despite these findings, there were no consistent treatment-related improvements in measures relating to CF-related diabetes, or CFRD, a common complication among children and adults…